Scribe Therapeutics, Inc. (SCTX) — real insider trading activity disclosed to the SEC, tracked automatically as new Form 4 filings are reported. Most recent: GORDON CARL L disclosed a transaction on 2026-07-27 worth $15,000,000.
Transactions disclosed by company insiders to the SEC on Form 4, most recent first.
| Insider | Role | Date | Shares | Value |
|---|---|---|---|---|
| Aghazadeh Behzad | Director | 2026-07-28 | 7,905 | $144,266 |
| AH Bio Fund II, L.P. | Insider | 2026-07-27 | 2,051,742 | $0 |
| AH Bio Fund II, L.P. | Insider | 2026-07-27 | 697,650 | $0 |
| AH Bio Fund II, L.P. | Insider | 2026-07-27 | 333,333 | $4,999,995 |
| Doudna Jennifer A | Insider | 2026-07-27 | 12,511 | $0 |
| ORBIMED ADVISORS LLC | Director | 2026-07-27 | 348,825 | $0 |
| ORBIMED ADVISORS LLC | Director | 2026-07-27 | 1,000,000 | $15,000,000 |
| GORDON CARL L | Director | 2026-07-27 | 348,825 | $0 |
| GORDON CARL L | Director | 2026-07-27 | 1,000,000 | $15,000,000 |
| Aghazadeh Behzad | Director | 2026-07-24 | 2,333,333 | $34,999,995 |
Data compiled from public SEC filings. This is informational reporting, not investment advice.
Carl L. Gordon, a director at Scribe Therapeutics, Inc. (SCTX), disclosed an open-market purchase of 1,000,000 shares at $15.00 per share, a bet worth exactly $15,000,000.00, according to a Form 4 filed with the SEC. The transaction is dated July 27, 2026. Following the purchase, Gordon’s stake stands at 1,348,825 shares, held indirectly through a … Read more
Another insider at Scribe Therapeutics, Inc. (SCTX) has stepped into the open market with a sizable purchase. According to a Form 4 filed with the SEC, AH Bio Fund II, L.P. bought 333,333 shares of the gene-editing biotech on July 27, 2026, paying $15.00 per share for a total outlay of $4,999,995.00. The transaction is … Read more
Insider trading today includes a notable open-market purchase at Scribe Therapeutics, Inc. (SCTX). A Form 4 filing shows OrbiMed Advisors LLC, listed as a director of the gene-editing company, bought 1,000,000 shares on July 27, 2026, at $15.00 per share for a total outlay of $15,000,000. The transaction was an open-market buy, meaning OrbiMed used … Read more
Behzad Aghazadeh, a Director and 10%+ owner of Scribe Therapeutics, Inc. (SCTX), purchased 7,905 shares of the gene-editing company on July 28, 2026, paying $18.25 per share for a total outlay of $144,266.25. The shares were acquired on the open market, meaning Aghazadeh used personal funds rather than receiving the stock through options or other … Read more